君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

已收盘 12-19 16:08:47

12.660

+0.060

+0.48%

最高12.680	最低12.300	成交量57.30万
今开12.500	昨收12.600	日振幅3.02%
总市值124.79亿	流通市值27.73亿	总股本9.86亿
成交额715.07万	换手率0.26%	流通股本2.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":12.66,"timestamp":1734595727014,"preClose":12.6,"halted":0,"volume":573000,"delay":0,"floatShares":219000000,"shares":985689871,"eps":-2.4887116,"marketStatus":"已收盘","marketStatusCode":5,"change":0.06,"latestTime":"12-19 16:08:47","open":12.5,"high":12.68,"low":12.3,"amount":7150701,"amplitude":0.030159,"askPrice":12.66,"askSize":1400,"bidPrice":12.6,"bidSize":2400,"shortable":3,"etf":0,"ttmEps":-1.9623125677983233,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1545580800000,"adjPreClose":12.6,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.73748,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":30.13,"timestamp":1734591600000,"preClose":29.97,"halted":0,"volume":5528238,"delay":0,"premium":"-60.83"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2492679443","title":"港股开盘，恒指开跌0.59%，科指开跌0.61%。生物医药股部分高开，复宏汉霖(02696.HK)开涨4.72%，君实生物(01877.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492679443","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492679443?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:22","pubTimestamp":1734398525,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["513600","HSI","161726","BK0239","YANG","399441","BK1583","02833","MCHmain","688180","BK1161","HSImain","HHImain","HSCEI","MHImain","BK1515","02696","07226","01877","HSTECH"],"gpt_icon":0},{"id":"2490674323","title":"对话君实生物CEO邹建军：成熟的Pharma需要研发、商业双驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2490674323","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490674323?lang=zh_cn&edition=full","pubTime":"2024-12-09 16:52","pubTimestamp":1733734332,"startTime":"0","endTime":"0","summary":"从2015年中国药审改革算起，国内创新药产业已经走过10年的“黄金时期”。最早一批生物科技公司过得怎么样？是否踩准了市场变化的每一个鼓点？君实生物（688180.SH）可能是最适合回答这个问题的公司之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412093262956257.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412093262956257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","01877","BK1583","BK1515"],"gpt_icon":0},{"id":"2489284531","title":"君实生物首席医学官Patricia Keegan：创新药出海需要恰当地选择MRCT或单一地区临床策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2489284531","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489284531?lang=zh_cn&edition=full","pubTime":"2024-12-06 20:26","pubTimestamp":1733487960,"startTime":"0","endTime":"0","summary":"会上，前美国食品药品监督管理局肿瘤卓越中心副主任、君实生物首席医学官Patricia Keegan博士发表了题为《创新与出海策略：我们该怎样对标全球先进治疗》的演讲。身为一名在全球药品监管领域有着深厚积淀的专家，Keegan博士在演讲中深度分析了中国医药企业布局创新药出海战略时，应该如何更好地对标国际标准。Keegan博士着重强调了企业恰当地选择单一地区或国际多中心临床试验可以在推动创新药物研发和全球市场准入中起到关键作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206203049ab6292e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206203049ab6292e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1574","01877","688180","06978","BK1515"],"gpt_icon":0},{"id":"2487155100","title":"君实生物：提名郦仲贤、鲁琨为公司第四届董事会独立非执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2487155100","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487155100?lang=zh_cn&edition=full","pubTime":"2024-11-29 21:10","pubTimestamp":1732885836,"startTime":"0","endTime":"0","summary":"证券日报网讯11月29日晚间，君实生物发布公告称，根据相关规定，经公司第四届董事会提名委员会资格审查，公司董事会同意提名郦仲贤先生、鲁琨女士为公司第四届董事会独立非执行董事候选人，任期自股东大会审议通过之日起至第四届董事会任期届满之日止。近日，公司董事会收到孟安明先生的书面辞呈，因其他工作安排，孟安明先生申请辞去公司第四届董事会独立非执行董事及战略委员会委员职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411293255210149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1583","BK1161","01877"],"gpt_icon":0},{"id":"2487071551","title":"君实生物：12月20日将召开2024年第一次临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2487071551","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487071551?lang=zh_cn&edition=full","pubTime":"2024-11-29 21:10","pubTimestamp":1732885833,"startTime":"0","endTime":"0","summary":"证券日报网讯11月29日晚间，君实生物发布公告称，公司计划于2024年12月20日14点30分在上海市浦东新区平家桥路100弄6号7幢15层召开2024年第一次临时股东大会。本次股东大会将采用现场投票和网络投票相结合的方式，将审议《关于使用剩余超募资金永久补充流动资金的议案》《关于变更公司注册地址、修订并办理工商变更登记的议案》《关于选举独立非执行董事的议案》等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411293255207121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1515","BK1161","01877"],"gpt_icon":0},{"id":"2487556674","title":"君实生物(01877)提名郦仲贤及鲁琨为独立非执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2487556674","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487556674?lang=zh_cn&edition=full","pubTime":"2024-11-29 20:45","pubTimestamp":1732884352,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)公布，董事会已考虑及批准提名郦仲贤及鲁琨为公司独立非执行董事候选人。选举郦仲贤及鲁琨为独立非执行董事将由公司股东于公司临时股东大会上提呈以供审议及批准。此外，孟安明因其他工作安排而辞任独立非执行董事及公司战略委员会成员。孟安明将继续履行彼之职责直至新任独立非执行董事获选举，而彼之辞任亦将于其后生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688180","BK0239","BK1515","01877","BK1583"],"gpt_icon":0},{"id":"2487953284","title":"君实生物：第四届董事会第五次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2487953284","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487953284?lang=zh_cn&edition=full","pubTime":"2024-11-29 18:11","pubTimestamp":1732875077,"startTime":"0","endTime":"0","summary":"证券日报网讯11月29日晚间，君实生物发布公告称，公司第四届董事会第五次会议审议通过了《关于将暂时闲置募集资金以通知存款等方式存放的议案》《关于变更公司注册地址、修订并办理工商变更登记的议案》等多项议案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411293255122340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","BK1515","BK1583","BK1161"],"gpt_icon":0},{"id":"2487532382","title":"君实生物：第四届监事会第四次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2487532382","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487532382?lang=zh_cn&edition=full","pubTime":"2024-11-29 18:11","pubTimestamp":1732875076,"startTime":"0","endTime":"0","summary":"证券日报网讯11月29日晚间，君实生物发布公告称，公司第四届监事会第四次会议审议通过了《关于将暂时闲置募集资金以通知存款等方式存放的议案》《关于作废处理2020年限制性股票激励计划部分已授予但尚未归属限制性股票的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411293255122287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1161","BK1583","01877"],"gpt_icon":0},{"id":"2487535159","title":"君实生物：关于提名独立非执行董事候选人及独立非执行董事辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2487535159","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487535159?lang=zh_cn&edition=full","pubTime":"2024-11-29 17:20","pubTimestamp":1732872000,"startTime":"0","endTime":"0","summary":"公司将按照法定程序尽快完成独立非执行董事的补选工作并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-29/doc-incxtqvm1818654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1161","01877","688180","BK0239","BK1515"],"gpt_icon":0},{"id":"2487759302","title":"《股市简讯》中国君实生物A/H股齐升，特瑞普利单抗新增四项适应症纳入国保","url":"https://stock-news.laohu8.com/highlight/detail?id=2487759302","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487759302?lang=zh_cn&edition=full","pubTime":"2024-11-29 13:43","pubTimestamp":1732859011,"startTime":"0","endTime":"0","summary":"《股市简讯》中国君实生物A/H股齐升，特瑞普利单抗新增四项适应症纳入国保* 中国生物科技公司--君实生物688180.SS周五盘中一度升6.6%，其H股1877.HK亦至多涨5.7%。* 君实生物周四公告，特瑞普利单抗注射液新增四项适应症纳入国家医保目录。这是国家医保目录中首次纳入非小细胞肺癌围手术期、肾癌、小细胞肺癌以及三阴性乳腺癌免疫疗法。公司将有望在相应适应症的市场推广上取得先发优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nL3T3N00DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK1515","688180","BK0239","BK1161","BK1583"],"gpt_icon":0},{"id":"2487055043","title":"君实生物现涨超5% 特瑞普利单抗4项新增适应症纳入新版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2487055043","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487055043?lang=zh_cn&edition=full","pubTime":"2024-11-29 11:50","pubTimestamp":1732852227,"startTime":"0","endTime":"0","summary":"君实生物（01877）早盘持续上扬，股价现涨5.39%，报13.30港元，成交额1216.25万港元。\n　　君实生物宣布，公司自主研发的抗PD-1单抗产品特瑞普利单抗（商品名：拓益®）新增4项适应症成功被纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》。新版国家医保目录将于2025年1月1日起正式实施。至此，拓益®在国内获批的10个适应症已全部纳入国家医保目录，是目录中唯一用于黑色素瘤、非小细胞肺癌围手术期、肾癌和三阴性乳腺癌治疗的抗PD-1单抗。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-29/doc-incxsxxv2130335.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-29/doc-incxsxxv2130335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["01877","BK1515","BK1583","BK1161"],"gpt_icon":0},{"id":"1189616355","title":"异动解读 | 特瑞普利单抗纳入医保新目录 君实生物股价盘中大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189616355","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189616355?lang=zh_cn&edition=full","pubTime":"2024-11-29 11:28","pubTimestamp":1732850910,"startTime":"0","endTime":"0","summary":"君实生物今日盘中股价大涨5.39%,引发了市场广泛关注。导致股价上涨的主要原因是其核心产品特瑞普利单抗新增4项适应症成功获批纳入国家最新的医保目录。随着4项新适应症即将于2025年1月纳入医保,特瑞普利单抗已覆盖了其所有10个国内获批适应症,成为医保目录中唯一用于上述四大肿瘤治疗的抗PD-1单抗。医保目录的扩大将大幅提升特瑞普利单抗的可及性和销量。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01877"],"gpt_icon":0},{"id":"2487066308","title":"君实生物盘中异动 早盘快速上涨5.07%报13.260港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2487066308","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487066308?lang=zh_cn&edition=full","pubTime":"2024-11-29 11:27","pubTimestamp":1732850848,"startTime":"0","endTime":"0","summary":"2024年11月29日早盘11时27分，君实生物股票出现波动，股价快速上涨5.07%。截至发稿，该股报13.260港元/股，成交量81.08万股，换手率0.37%，振幅5.07%。资金方面，该股资金流入667.055万港元，流出266.964万港元。君实生物股票所在的生物技术行业中，整体涨幅为1.72%。其相关个股中，东曜药业-B、百济神州、君实生物涨幅较大，振幅较大的相关个股有晶泰科技、来凯医药-B、博安生物，振幅分别为10.20%、7.80%、6.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112911272898e45312&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112911272898e45312&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1515","688180","BK1161","BK1583"],"gpt_icon":0},{"id":"2487033703","title":"君实生物(01877)上涨5.07%，报13.26元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2487033703","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487033703?lang=zh_cn&edition=full","pubTime":"2024-11-29 11:27","pubTimestamp":1732850846,"startTime":"0","endTime":"0","summary":"11月29日，君实生物(01877)盘中上涨5.07%，截至11:27，报13.26元/股，成交1049.6万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法，特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年三季报，君实生物营业总收入12.71亿元、净利润-9.27亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/29112745827969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","688180","BK1515","01877","BK1161","BK1583"],"gpt_icon":0},{"id":"2487704503","title":"港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗4项新增适应症纳入新版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2487704503","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487704503?lang=zh_cn&edition=full","pubTime":"2024-11-29 11:02","pubTimestamp":1732849356,"startTime":"0","endTime":"0","summary":"消息面上，君实生物宣布，公司自主研发的抗PD-1单抗产品特瑞普利单抗新增4项适应症成功被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》。新版国家医保目录将于2025年1月1日起正式实施。至此，拓益在国内获批的10个适应症已全部纳入国家医保目录，是目录中唯一用于黑色素瘤、非小细胞肺癌围手术期、肾癌和三阴性乳腺癌治疗的抗PD-1单抗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688180","BK1161","BK1583","BK1515","BK0239","01877"],"gpt_icon":0},{"id":"2487479113","title":"君实生物(01877.HK)拓益新增4项适应症获纳入新版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2487479113","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487479113?lang=zh_cn&edition=full","pubTime":"2024-11-29 03:21","pubTimestamp":1732821660,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布，公司产品特瑞普利单抗注射液(商品名：拓益)新增4项适应症成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》乙类范围，新版国家医保目录将于2025年1月1日起正式实施。至今，拓益内地获批的10项适应症已全部纳入国家医保目录。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-28 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200529130906781_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200529130906781_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1400399/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1515","BK0239","01877","688180","BK1583"],"gpt_icon":0},{"id":"2486395930","title":"君实生物(01877)：拓益®新增适应症纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486395930","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486395930?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:54","pubTimestamp":1732787669,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，近日，上海君实生物医药科技股份有限公司(以下简称“公司”)产品特瑞普利单抗注射液(商品名：拓益®，产品代号：JS001)新增4项适应症成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》(以下简称“国家医保目录”)乙类范围。新版国家医保目录将于2025年1月1日起正式实施。截至本公告披露日，拓益®在中国内地获批的10项适应症已全部纳入国家医保目录，是国家医保目录中唯一用于黑色素瘤、非小细胞肺癌围手术期、肾癌和三阴性乳腺癌治疗的抗PD-1单抗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0239","BK1161","01877","688180","BK1515"],"gpt_icon":0},{"id":"2486954033","title":"君实生物(01877.HK)拓益新增适应症被纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486954033","media":"阿斯达克财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486954033?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:54","pubTimestamp":1732787640,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布，特瑞普利单抗注射液，商品名为拓益，新增4项适应症成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》乙类范围。新版国家医保目录将于2025年1月1日起正式实施。公司指，目前拓益在内地获批的10项适应症已全部纳入国家医保目录，是国家医保目录中唯一用于黑色素瘤、非小细胞肺癌围手术期、肾癌和三阴性乳腺癌治疗的抗PD-1单抗。(ha/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-28 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190121165959803_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190121165959803_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1400329/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","BK1161","688180","BK1515","BK1583","01877"],"gpt_icon":0},{"id":"2486397804","title":"君实生物宣布拓益®4项新增适应症正式纳入新版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486397804","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486397804?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:33","pubTimestamp":1732786380,"startTime":"0","endTime":"0","summary":"上海2024年11月28日 /美通社/ -- 北京时间11月28日，君实生物宣布，公司自主研发的抗PD-1单抗产品特瑞普利单抗新增4项适应症成功被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》。新版国家医保目录将于2025年1月1日起正式实施。至此，拓益在国内获批的10个适应症已全部纳入国家医保目录，是目录中唯一用于黑色素瘤、非小细胞肺癌围手术期、肾癌和三阴性乳腺癌治疗的抗PD-1单抗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4567927_ZH67927_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4588","BK4213","01877","ALK","688180","BK1515","BK4008","BK4500","BK0239","BK4585","TGA","BK1161","BK1583"],"gpt_icon":0},{"id":"2486469367","title":"君实生物拓益新增4项适应症纳入医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486469367","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486469367?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:41","pubTimestamp":1732783260,"startTime":"0","endTime":"0","summary":"财中社11月28日电君实生物（688180/01877）发布自愿披露公告，宣布其产品特瑞普利单抗注射液（拓益?）新增4项适应症成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》的乙类范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411283253767052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1515","01877","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.083},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.2046},{"period":"6month","weight":0.117},{"period":"1year","weight":-0.3438},{"period":"ytd","weight":-0.3519}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物科技有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.122873},{"month":2,"riseRate":0.833333,"avgChangeRate":0.02917},{"month":3,"riseRate":0.666667,"avgChangeRate":0.049114},{"month":4,"riseRate":0.833333,"avgChangeRate":0.112597},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.034116},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.02585},{"month":7,"riseRate":0.5,"avgChangeRate":-0.055172},{"month":8,"riseRate":0,"avgChangeRate":-0.083168},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.027724},{"month":10,"riseRate":0.333333,"avgChangeRate":0.015959},{"month":11,"riseRate":0.666667,"avgChangeRate":0.058946},{"month":12,"riseRate":0.666667,"avgChangeRate":0.138596}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}